MAIA Valuation
Maia Biotechnology Inc
$
1.570
- Overview
- Forecast
- Valuation
- Earnings
MAIA Relative Valuation
MAIA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MAIA is overvalued; if below, it's undervalued.
Historical Valuation
Maia Biotechnology Inc (MAIA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.44. The fair price of Maia Biotechnology Inc (MAIA) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.55
Fair
-2.06
PE
1Y
3Y
5Y
Trailing
Forward
-1.13
EV/EBITDA
Maia Biotechnology Inc. (MAIA) has a current EV/EBITDA of -1.13. The 5-year average EV/EBITDA is -1.32. The thresholds are as follows: Strongly Undervalued below -2.42, Undervalued between -2.42 and -1.87, Fairly Valued between -0.77 and -1.87, Overvalued between -0.77 and -0.21, and Strongly Overvalued above -0.21. The current Forward EV/EBITDA of -1.13 falls within the Historic Trend Line -Fairly Valued range.
-1.14
EV/EBIT
Maia Biotechnology Inc. (MAIA) has a current EV/EBIT of -1.14. The 5-year average EV/EBIT is -1.24. The thresholds are as follows: Strongly Undervalued below -2.27, Undervalued between -2.27 and -1.75, Fairly Valued between -0.72 and -1.75, Overvalued between -0.72 and -0.20, and Strongly Overvalued above -0.20. The current Forward EV/EBIT of -1.14 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Maia Biotechnology Inc. (MAIA) has a current PS of 0.00. The 5-year average PS is 1.56. The thresholds are as follows: Strongly Undervalued below -5.24, Undervalued between -5.24 and -1.84, Fairly Valued between 4.97 and -1.84, Overvalued between 4.97 and 8.37, and Strongly Overvalued above 8.37. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Maia Biotechnology Inc. (MAIA) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.64. The thresholds are as follows: Strongly Undervalued below -2.29, Undervalued between -2.29 and -1.46, Fairly Valued between 0.18 and -1.46, Overvalued between 0.18 and 1.00, and Strongly Overvalued above 1.00. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Maia Biotechnology Inc. (MAIA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Maia Biotechnology Inc (MAIA) has a current Price-to-Book (P/B) ratio of 9.10. Compared to its 3-year average P/B ratio of 13.49 , the current P/B ratio is approximately -32.56% higher. Relative to its 5-year average P/B ratio of 13.38, the current P/B ratio is about -32.01% higher. Maia Biotechnology Inc (MAIA) has a Forward Free Cash Flow (FCF) yield of approximately -35.43%. Compared to its 3-year average FCF yield of -33.71%, the current FCF yield is approximately 5.10% lower. Relative to its 5-year average FCF yield of -33.40% , the current FCF yield is about 6.06% lower.
12.19
P/B
Median3y
13.49
Median5y
13.38
-34.92
FCF Yield
Median3y
-33.71
Median5y
-33.40
Competitors Valuation Multiple
The average P/S ratio for MAIA's competitors is 0.09, providing a benchmark for relative valuation. Maia Biotechnology Inc Corp (MAIA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MAIA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MAIA in the past 1 year is driven by Unknown.
People Also Watch
ICAD
ICAD Inc
3.870
USD
+3.62%
CGBS
Crown LNG Holdings Ltd
0.017
USD
-64.69%
FBIO
Fortress Biotech Inc
2.010
USD
+4.69%
CLST
Catalyst Bancorp Inc
12.556
USD
-0.07%
OPI
Office Properties Income Trust
0.239
USD
+1.27%
NVNI
Nvni Group Ltd
0.688
USD
+9.21%
PVL
Permianville Royalty Trust
1.850
USD
+0.82%
XLO
Xilio Therapeutics Inc
0.700
USD
+2.94%
LSB
LakeShore Biopharma Co Ltd
0.810
USD
+1.00%
CELU
Celularity Inc
3.060
USD
-5.26%
FAQ
Is Maia Biotechnology Inc (MAIA) currently overvalued or undervalued?
Maia Biotechnology Inc (MAIA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.44. The fair price of Maia Biotechnology Inc (MAIA) is between to according to relative valuation methord.
What is Maia Biotechnology Inc (MAIA) fair value?
How does MAIA's valuation metrics compare to the industry average?
What is the current P/B ratio for Maia Biotechnology Inc (MAIA) as of Aug 13 2025?
What is the current FCF Yield for Maia Biotechnology Inc (MAIA) as of Aug 13 2025?
What is the current Forward P/E ratio for Maia Biotechnology Inc (MAIA) as of Aug 13 2025?